Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
14C epaminurad
- Development stage
- Unknown
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
14C epaminurad is a radiolabeled version of epaminurad (URC102), a selective urate transporter 1 (URAT1) inhibitor developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. As a uricosuric agent, epaminurad works by inhibiting the SLC22A12 transporter in the proximal tubule of the kidney, thereby preventing the reabsorption of uric acid and promoting its excretion in urine. The 14C-labeled formulation is specifically utilized in Phase 1 mass balance and metabolite profiling studies to characterize the absorption, distribution, metabolism, and excretion (ADME) of the drug in humans. While the parent compound is in Phase 3 clinical development, the 14C version is a critical tool for understanding the drug's metabolic pathways and recovery.
- Other names
- 14C-epaminurad[14C]epaminurad14C-labeled epaminurad
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on 14C epaminurad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 14C epaminurad.